• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Lou Gehrigs Disease - Global Strategic Business Report Product Image

Lou Gehrigs Disease - Global Strategic Business Report

  • Published: April 2010
  • Region: World
  • 258 Pages
  • Global Industry Analysts, Inc

FEATURED COMPANIES

  • Avicena Group Inc.
  • Ceregene Inc.
  • CytRx Corporation
  • Genzyme Corporation
  • Isis Pharmaceuticals Inc.
  • Knopp Neurosciences
  • MORE

This report analyzes the Global market for Lou Gehrigs Disease in US$ Million. Annual estimates and forecasts are provided for the period 2006 through 2015. The report profiles 37 companies including many key and niche players such as Aeolus Pharmaceuticals, Inc., Amorfix Life Sciences Ltd., Avicena Group, Inc., Ceregene, Inc., CytRx Corporation, Genzyme Corporation, Isis Pharmaceuticals, Inc., Knopp Neurosciences, Maas Biolab, NeuroNova AB, Sygnis Pharma AG, Teva Pharmaceutical Industries Ltd., and Trophos SA. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.

For information on site licence pricing please click on Enquire before buying

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-3
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3

II. Executive Summary

1. INDUSTRY OVERVIEW II-1
Global Market Analysis II-1
Sanofi-Aventis - The Only Drug Maker for ALS II-1
Rilutek II-1
Prevalence and Incidence of ALS II-2
The United States II-2
Canada II-2
Table 1: Mortality Rate of ALS in Canada - A Historic Review
(includes corresponding Graph/Chart) II-3
The United Kingdom II-3
New Zealand II-3
Australia II-3
Table 2: Mortality Rate in Australia for Years 2005 through
2007(includes corresponding Graph/Chart) II-3

2. AMYOTROPHIC LATERAL SCLEROSIS - AN INSIGHT II-4
Major Types of ALS II-4
Etiology II-5
Exact Causes of ALS Still Unknown II-6
Major Milestones in ALS Treatment Arena II-6
Diagnosis II-6
Symptoms of ALS II-7
Initial symptoms II-7
Emerging Symptoms II-8
Use of BiPAP, IPPV and Mechanical Respirators in ALS II-8
Measures to Deal with ALS Problems II-9
Treatment II-9
Symptomatic Treatment II-10

3. POTENTIAL THERAPIES FOR ALS II-11
Neurotrophic Factors II-11
Insulin-like Growth Factor II-11
Vascular endothelial growth factor II-11
Sangamo BioSciences to Develop SB 509 II-12
Smaller Molecules II-12
RNA Interference II-12
Stem Cells Offer New Hope II-12
Studies on Stem Cells II-12
LTC to Develop New Lou Gehrigs Disease Models II-13
Herbal Treatment II-13
Lithium: A potential Treatment for ALS II-13
Advancements in ALS Genetics II-13
Select Pipeline Drugs for ALS Under Clinical Trials (2009) II-14

4. CLINICAL TRIALS AND RESEARCH STUDIES II-15
CytRx Initiates Phase 2/3 Clinical Trial for Arimoclomol II-15
New Treatment for ALS Patients II-15
KNS-760704 Receives Orphan Designation II-15
KNS-760704 Enters Phase 2 Study II-15
Maas Biolab SBIR Initiates Phase 2 for Cyclosporin II-16
Researchers Identify New Gene for ALS II-16

5. RECENT INDUSTRY ACTIVITY II-17
Merck to Purchase Insmed’s Assets II-17
NeuroNova Signs Agreement with Genentech II-17
Insmed Inks a Deal with IDIS to Organize NPPs for IPLEXTM II-17
Teva to Extend Branded Products in Niche Specialty Diseases II-18
Asklepios and ALS TDI Develop Latest Therapeutic Delivery
Alternatives for ALS Treatment II-18
Medicare Extends DME Coverage of HFCWO to Cure Neuromuscular
Disorders II-18
Neuralstem and Hospital of Taiwan Collaborate for Development
of Neural Stem Cell Therapies II-18
Life Technologies to Create Neurodegenerative Disease Models II-19
Medicare Extends the Coverage of HFCWO to Cure Neuromuscular
Disorders II-19
Sygnis Obtains Orphan Drug Status for AX200 in Spinal Cord
Injury Treatment II-19
Insmed Obtains Royalty-Free Global Rights for IPLEXTM II-20
Q Therapeutics Collaborates with Johns Hopkins Research Team II-20
Aldagen to Collaborate with UC Davis II-20
ALS TDI Collaborates with CSC II-20
ALS TDI and Allen Institute for Brain Science Enter into
Agreement II-21
Amorfix Completes Research Partnership with Biogen Idec II-21
Isis Receives Orphan Drug Designation II-21
Prize4Life Endorses BrainStorm to Develop ALS Cure II-22
ALS TDI Selects Microbix to Manufacture Adenoviruses II-22
Maas BiolAB Receives SBIR Grant II-22
Neuralstem Collaborates with University of Michigan II-22
ALS TDI and MDA Collaborate II-23

6. PLAYERS VENTURING THE ALS MARKET II-24
Aeolus Pharmaceuticals, Inc. (US) II-24
Amorfix Life Sciences Ltd. (Canada) II-24
Avicena Group, Inc. (US) II-24
Ceregene, Inc. (US) II-25
CytRx Corporation (US) II-25
Genzyme Corporation (US) II-25
Isis Pharmaceuticals, Inc. (US) II-26
Knopp Neurosciences (US) II-26
Maas Biolab (US) II-26
NeuroNova AB (Sweden) II-27
Sygnis Pharma AG (Germany) II-27
Teva Pharmaceutical Industries Ltd. (Israel) II-27
Trophos SA (France) II-28

7. ASSOCIATIONS INVOLVED IN ALS RESEARCH II-29
Northeast Amyotrophic Lateral Sclerosis Consortium (US) II-29
Muscular Dystrophy Association (MDA) II-29
The ALS Association II-29
ALS Society of Canada II-29
ALS Therapy Development Institute II-30
Motor Neurone Disease Research Institute of Australia II-30

8. GLOBAL MARKET PERSPECTIVE II-31
Table 3: World Recent Past, Current & Future Analysis for Lou
Gehrigs Disease by Geographic Region - US, and Rest of World
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2006 through 2015 (includes
corresponding Graph/Chart) II-31

Table 4: World 10-Year Perspective for Lou Gehrigs Disease
by Geographic Region -Percentage Breakdown of Sales for US,
and Rest of World Markets for Years 2006, 2009 & 2015 II-31

III. COMPETITIVE LANDSCAPE

Total Companies Profiled: 37 (including Divisions/Subsidiaries - 38)

---------
Region/Country Players
---------
The United States 30
Canada 1
Europe 6
France 2
Germany 1
The United Kingdom 1
Rest of Europe 2
Middle-East 1
---------

- Aeolus Pharmaceuticals Inc.
- Amorfix Life Sciences Ltd.
- Avicena Group Inc.
- Ceregene Inc.
- CytRx Corporation
- Genzyme Corporation
- Isis Pharmaceuticals Inc.
- Knopp Neurosciences
- Maas Biolab
- NeuroNova AB
- Sygnis Pharma AG
- Teva Pharmaceutical Industries Ltd.
- Trophos SA

Format Properties
Electronic (PDF) The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.
Hard Copy A printed copy of the report will be shipped to you.
1 - 5 Users The report will be emailed to you. The report is sent in PDF format. This is a 1-5 user licence, allowing up to five users have access to the product.
1 - 10 Users The report will be emailed to you. The report is sent in PDF format. This is a 1-10 user licence, allowing up to ten users have access to the product.
1 - 15 Users The report will be emailed to you. The report is sent in PDF format. This is a 1-15 user licence, allowing up to fifteen users have access to the product.
Note: Product cover images may vary from those shown
More

RELATED PRODUCTS

Our Clients

Our clients' logos